Mammalian TOR Controls One of Two Kinase Pathways Acting upon nPKCδ and nPKCε*

Abstract

There are three conserved phosphorylation sites in protein kinase C (PKC) isotypes that have been termed priming sites and play an important role in PKC function. The requirements and pathways involved in novel (nPKC) phosphorylation have been investigated here. The evidence presented for nPKCδ shows that there are two independent kinase pathways that act upon the activation loop (Thr-505) and a C-terminal hydrophobic site (Ser-662) and that the phosphorylation of the Ser-662 site is protected from dephosphorylation by the Thr-505 phosphorylation. Both phosphorylations require C1 domain-dependent allosteric activation of PKC. The third site (Ser-643) appears to be an autophosphorylation site. The serum-dependent phosphorylation of the Thr-505 and Ser-662 sites increases nPKCδ activity up to 80-fold. Phosphorylation at the Ser-662 site is independently controlled by a pathway involving mammalian TOR (mTOR) because the rapamycin-induced block of its phosphorylation is overcome by co-expression of a rapamycin-resistant mutant of mTOR. Consistent with this role of mTOR, amino acid deprivation selectively inhibits the serum-induced phosphorylation of the Ser-662 site in nPKCδ. It is established that nPKCε behaves in a manner similar to nPKCδ with respect to phosphorylation at its C-terminal hydrophobic site, Ser-729. The results define the regulatory inputs to nPKCδ and nPKCε and establish these PKC isotypes downstream of mTOR and on an amino acid sensing pathway. The multiple signals integrated in PKC are discussed.

  • Abbreviations:
    PKC
    protein kinase C
    PRK
    protein kinase C-related kinase
    PI
    phosphatidylinositol
    PtdIns-3
    4,5-P3, phosphatidylinositol 3,4,5-trisphosphate
    p70S6k
    70-kDa protein from S6-kinase
    PAGE
    polyacrylamide gel electrophoresis
    FCS
    fetal calf serum
    TPA
    tetradecanoyl phorbol acetate
    BIM I
    bisindolylmaleimide I
    mTOR
    mammalian TOR
    mTORrap-res
    rapamycin-resistant mTOR
    DAG
    diacylglycerol
    • Received June 23, 1999.
    • Revision received August 10, 1999.
    Table of Contents

    Submit your work to JBC.

    You'll be in good company.